Page 222 - 2021_09-Haematologica-web

Letters to the Editor
tion of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
3. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multi- ple myeloma. Blood. 1995;85(4):863-872.
4. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-1254.
5. Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated sig- naling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 2001;2(1):42-53.
6. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. Interleukin-6- dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associat- ed with Stat3 activation. Blood. 2004;103(1):242-251.
7. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115.
8.Burger R, Günther A, Klausz K, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade effi- ciently inhibits myeloma growth. Haematologica. 2017;102(2):381- 390.
9. Puthier D, Bataille R, Amiot M. IL-6 up-regulates Mcl-1 in human
myeloma cells through JAK/STAT rather than Ras/MAP kinase
pathway. Eur J Immunol. 1999;29(12):3945-3950.
10. Slomp A, Peperzak V. Role and regulation of pro-survival BCL-2 pro-
teins in multiple myeloma. Front Oncol. 2018;8:533.
11.Gupta V, Matulis SM, Conage-Pough JE, et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in
multiple myeloma. Blood. 2017;129(14):1969-1979.
12. Abdollahi P, Vandsemb EN, Hjort MA, et al. Src family kinases are regulated in multiple myeloma cells by phosphatase regenerating
liver-3. Mol Cancer Res. 2016;15(1):69-77.
13. Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is
tolerable and effective in diverse cancer models. Nature.
2016;538(7626):477-482.
14. Wei AH, Roberts AW, Spencer A, et al. Targeting Mcl-1 in hemato-
logic malignancies: rationale and progress. Blood Rev.
2020;44:100672.
15.Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2
inhibitors synergize to counteract bone marrow stromal cell-
induced protection of AML. Blood. 2017;130(6):789-802.
16. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Cancer Res. 2007;67(4):1783-92.
2510
haematologica | 2021; 106(9)